




LIFECARE

Semi Annual Report

1H 2023



Contents

- Contents 2
- CEO’s Statement 3
- Financials - Summary 7
- Clinical trials - Progress 14
- Financial calendar 15
- Share capital increases 15
- Shareholders as of 27.02.2023..... 16
- Disclaimer 17
- Contact..... 18
- About Lifecare..... 18

CEO's Statement

TOWARDS MARKET READINESS

Lifecare has shown major progress in our plan to bring the smallest Continuous Glucose Monitor system to the market. Testing in live tissue, implementation of Quality Management System and set up of manufacturing capabilities form the three main pillars in our market-oriented development. Throughout 1H 2023 we have shown significant progress on the path towards the market, and we are confident that we will meet our goal to be market-ready in 2024.

The results from studies concluded in 1H 2023 and the status of the initial product development phase as well as strategic adjustments strengthen our belief that we will be market ready in 2024.

LFC-SEN-001 STUDY RESULTS: ACCURACY AND LONGEVITY

Our first-in-human Clinical Development Study (LFC-SEN-001) was finalized in 1H 2023. The study was designed to obtain a clear proof-of-concept in humans and to provide data for signal read-out and accuracy. In this clinical phase we have used a wired version of our sensor and the complete study has been conducted in controlled environment at Lifecare Laboratories facilities in Mainz, Germany.

Previous studies in-vivo (in living organisms) were successfully conducted in pigs, and we were confident that we would obtain the same clinical proof of concept in humans. From a scientific and product development point of view, the main importance of the study was to obtain data with the purpose to develop predictive algorithms for implementation in our final product. For this reason, the study was designed with a wired read-out, to ensure sound and strong signal readouts. For our upcoming in-vivo studies we will implement a wireless readout, as we now have a solid basis for the continued work on our algorithms.

To facilitate the study, we embedded our sensor in a needle, and implanted the device in-vivo on both healthy subjects and subjects with diabetes. While the study protocol allowed us to have the sensors implanted up to three days, we were able to explant the sensors and transfer a few sensors to continued experiments in-vitro (in the lab) to obtain longevity data. This maneuver was important from an experimental point of view to achieve soundproof of our longevity potential, but also confirm the unprecedented robustness of our clinical sensor.

Data from LFC-SEN-001 confirm a solid clinical accuracy of our technology (Sencell). The mean average of absolute error (MARD) between Sencell and matched relative reference values in the study was 9,6%, meaning that our sensor technology is in line with the gold standard for glucose monitoring (rang 5%-10%). At the current development stage, the sensor sensitivity and algorithm development provide accuracy far better than expected.

Furthermore, two weeks into Q3 2023 we concluded the continued experiments in-vitro with a longevity reaching an operational lifetime of more than 24 weeks (172 days), with a sensor chemistry shelf life of almost 27 weeks (187 days). This confirms both that our technology has a superior longevity compared to existing needle-based CGM sensors, as well as an encouraging stability of the chemistry used in the in the sensor. This experiment validates the potential of Sencell to provide long-term and accurate glucose monitoring for people with diabetes, while reducing the need for frequent sensor replacements.

QUALITY IN REGULATORY CONTEXT

Our core mission is to introduce an implantable device for medical use to the market, hence we are strongly dependent on solid quality measures in all parts of the Lifecare organisation. In 2H 2022 we increased our focus on Quality Management with regulatory compliance based on a structured approach to achieve the certifications necessary to produce medical equipment.

The first target in our plan was to obtain the ISO 9001 certification for Lifecare Laboratory. This goal was met in Q1 2023, and we are now in progress towards compliance and later certification of ISO 13485.

The current ongoing process in our regulatory preparations is to ensure that Lifecare Laboratory will be ready for ISO 13485 audit in 2H 2023. On the basis of ISO 13485 certification, technical data from the upcoming studies (LFC-SEN-002 and LFC-SEN-003) and manufacturing readiness, we will be positioned to CE mark our product as a medical device for humans.

MANUFACTURING PREPARATIONS – AUTOMATION Q2 2024

Preparations for manufacturing are essential in the context of both regulatory affairs and commercial outlook. We do believe that manufacturing readiness and manufacturability is the most important process in Lifecare in the near future.

Lifecare has decided to set up our first production facility in the immediate vicinity of our existing location in Mainz, Germany. We have entered a lease agreement for close to 1000 sqm in a new building under construction. While these premises will be ready for take-over in mid 2025, we plan to establish an intermediate production-line in our existing facilities in Mainz. This first production line will include automation of key production processes on the nano and micro scale, ensuring high quality sensor and system reproducibility.

To overlook the manufacturing preparations, we have increased our team with a VP of Manufacturing and are in the process of hiring additional staff with industrial experience. Preparations initiated early in Q2 2023 has already led to a significant internal progress towards production readiness. We expect to be ready to start the first automated production operations by end of Q2 2024.

This first line of automated production will imply a significant milestone in the Sencell development for several reasons. Firstly, a confirmation of "Manufacturability" is essential for commercialization. We are confident that we will manage the development and engineering necessary to reach production maturity. Second, advancements in production preparations are necessary to gain competence, experience, and data for technical documentation for the future CE mark. Third, reaching the milestone of automated production will position Lifecare as market ready independent of the progression of CE marking.

SYNERGIES AND OPPORTUNITIES IN THE VETERINARY MARKET

In Q1 we communicated that we would start to work on investigating additional technology utilisation. We have identified relevant additional markets for our technology and on this basis launched the spin-off company Lifecare Veterinary. The purpose is clear; to assist pets with diabetes with our existing technology. The market opportunity within the dog and cat market is unquestionable, and the regulatory frameworks are less complex compared to the human market.

On the course of our development towards automated production, and regulatory progress towards the CE mark as a medical device (for humans), we see significant synergies towards the animal market without jeopardizing the progress of our main development.

Lifecare Veterinary has established a cooperation with the Norwegian Veterinary College, which is a part of the Norwegian University of Environmental and Biosciences (NMBU). Depending on the progress of regulatory approvals, Lifecare Veterinary will start longevity and biocompatibility studies with dogs during the autumn of 2023, in cooperation with the Veterinary College.

Aligned with the preparations for automated production and the fact that the veterinary device market is less regulated compared to the human medical device market, we expect to be ready to enter the veterinary market in 2024 – and uphold our progress plan towards CE marking, necessary to enter the human market.

UPCOMING STUDY LFC-SEN-002

The next action of studies is to investigate and document our technology longevity (in-vivo) and biocompatibility in-vivo. This action was planned as a clinical (human) study, but on the basis of both ethical and commercial considerations we have decided to proceed with LFC-SEN-002 as a study in dogs. Following the results of LFC-SEN-001, we see no need for additional proof of concept in human subjects, as study in dogs will provide the necessary data in terms of longevity (in-vivo) and biocompatibility. In fact, longevity and biocompatibility studies are normally conducted in animals.

OUTLOOK SUMMARY

- Q3 Software for automated production in SEM: order and start customizing.
- Q3 get approval for LFC-SEN-002
- Q3/Q4 ISO 13485 compliant/ready for audit
- Q4 placing order for SEM for production.
- Q4 placing order for specialized production units for filling and sealing.
- Q4 start LFC-SEN-002
- Q4 start preparing for LFC-SEN-003



CEO

Joacim Holter

Market insight

DIABETES PREVALENCE: 2050

In June 2023 the group “GBD 2021 Diabetes Collaborators” published a series article in the Lancet Diabetes & Endocrinology (The Lancet), including a systematic analysis of the global diabetes burden and projections of global diabetes prevalence until 2050.

The systemic analysis in the Lancet reveal that the prevalence of diabetes increased with an accelerating 90,5% from 1990 to 2021. Furthermore, the study conclusion forecasts that the number of people (at all ages) with diabetes worldwide will increase from 529 million in 2021 to 1,3 billion in 2050. Previous projections from the International Diabetes Federation in 2021 (IDF Diabetes Atlas) has projected an increase in the age group 20 – 79 years from 537 million in 2021 to 783 million in 2050.

The scientists in GDB 2021 Diabetes Collaborators define diabetes as a **monumental global health threat posing increasing challenges to public health and healthcare systems worldwide** and point out that the World Health Organization has identified diabetes as one of three target diseases in its Global Action Plan for Prevention and Control of NCD’s.





Figure 4: Global age-standardised prevalence of type 1 and type 2 diabetes from 1990 through 2050 forecasts
The shaded area represents 95% uncertainty intervals. Total diabetes is the sum of type 1 and type 2 diabetes.

Source 2 Lancet 2023; 402: 203–34

GLOBAL CGM USERBASE

While the first generation of Continuous Glucos Monitoring (CGM) devices became available in the market in the first years from 2000, the userbase has exploded over the last few years in line with increased market availability and affordability. However, the gap between the estimated numbers of persons with diabetes worldwide and estimated CGM userbase is enormous.

In Q2 2023 Closer Look Memorandum published “Diabetes Technology 1Q23 Industry Roundup” estimating that the global CGM passed 7 million in Q1 2023.



Source 1 Closer Look Memorandum “Diabetes Technology 1Q23 Industry Roundup”

Financials - Summary

GROWTH IN GROUP ORGANIZATION

Enhanced activities and operations have led to advancements in product development, regulatory compliance, and manufacturing preparations.



The German public-funded Covid-19 test scheme, which greatly contributed to revenue growth in 2022, has now concluded. Consequently, Lifecare Laboratory GmbH's revenue for 2023 has reverted to a level comparable with third-party revenue figures before the pandemic.

The increased development activity, in conjunction with stabilized third-party revenue, has affected the Group's financial performance in comparison to the preceding year, 2022. The total Group revenue for the initial half of 2023 stands at 3.84 MNOK. This represents a decrease in revenue of -4,84 MNOK when compared to the same period in 2022.

The Group's ongoing expansion and intensified operational undertakings have naturally led to increased salary and personnel costs. Notably, the operating result for the first half of the year is -14,26 MNOK, compared to -6.36 MNOK in the first half of 2022.

KEY FINANCIAL

Financial statements 30 June 2023 unaudited (MNOK),	Q2 2023	Q2 2022	1H 2023	1H 2022
Revenue	1,23	6,70	3,84	8,68
Salaries and personnel costs	-4,26	-2,43	-8,27	-4,15
Other operating costs	-4,50	-5,90	-9,48	-11,02
Sum operating result	-7,53	-1,63	-13,91	-6,49
Net finance	-0,20	0,14	-0,35	0,13
Sum	-7,73	-1,48	-14,26	-6,36
Equity	41,21	19,43	41,21	19,43
Total Assets	53,55	38,63	53,55	38,63
Earning per share	-0,068	-0,019	-0,125	-0,069



CONSOLIDATED FIGURES, LIFECARE GROUP (UNAUDITED FIGURES)

Q2	Q2			1H	1H
IFRS	IFRS	NOK		IFRS	IFRS
2023	2022			2023	2022
1 229 526	6 701 066	OPERATING INCOME		3 840 293	8 678 620
-4 260 118	-2 427 184	SALARIES AND OTHER PERSONNELL EXP.		-8 268 236	-4 153 594
-564 997	-85 157	DEPRECIATION AND AMORTIZATION COSTS	2	-997 907	-607 471
-253 932	-182 287	AMORTIZATION ROA	2	-499 853	-362 544
-3 680 385	-5 632 486	OTHER OPERATING COSTS		-7 982 460	-10 049 311
-8 759 432	-8 327 115	<i>OPERATING EXPENSES</i>		-17 748 455	-15 172 921
-7 529 906	-1 626 049	OPERATING RESULT		-13 908 162	-6 494 302
46 394	201 880	FINANCE INCOME		59 426	220 147
-249 399	-58 271	FINANCE COSTS		-414 341	-89 632
-203 005	143 609	<i>NET FINANCIAL ITEMS</i>		-354 915	130 515
-7 732 911	-1 482 441	ORDINARY RESULT BEFORE TAXES		-14 263 077	-6 363 787
-432 065	-496 353	TAXES		-432 065	-496 353
-8 164 977	-1 978 793	ORDINARY RESULT		-14 695 143	-6 860 140
-0,069	-0,020	Earnings per share (basic)		-0,125	-0,069

BALANCE SHEET, LIFECARE GROUP (UNAUDITED FIGURES)

Q2	Q2	NOK	1H	1H
IFRS	IFRS		IFRS	IFRS
2023	2022		2023	2022
5 758 524	6 711 361	LICENCES AND PATENTS	5 758 524	6 711 361
7 330 832	7 119 574	GOODWILL	7 330 832	7 119 574
13 089 356	13 830 935	INTANGIBLE ASSETS	13 089 356	13 830 935
2 913 240	1 231 234	MACHINERY AND EQUIPMENT	2 913 240	1 231 234
-	-	INVESTMENTS IN AFFILIATED COMPANIES	-	-
3 545 125	3 947 057	RIGHT-OF-USE ASSET	3 545 125	3 947 057
6 458 365	5 178 291	TOTAL FIXED ASSETS	6 458 365	5 178 291
-813 550	2 074 696	RECEIVABLES	-813 550	2 074 696
8 118 376	6 243 776	OTHER CURRENT FINANCIAL ASSETS	8 118 376	6 243 776
26 694 434	11 306 150	CASH AND CASH EQUIVALENTS	26 694 434	11 306 150
33 999 260	19 624 622	TOTAL CURRENT ASSETS	33 999 260	19 624 622
53 546 981	38 633 848	TOTAL ASSETS	53 546 981	38 633 848
87 453 295	42 050 498	PAID UP EQUITY	87 453 295	42 050 498
-46 242 339	-22 624 928	RETAINED EQUITY	-46 242 339	-22 624 928
41 210 956	19 425 570	TOTAL EQUITY	41 210 956	19 425 570
1 640 914	1 538 357	DEFERRED TAX	1 640 914	1 538 357
5 541 395	6 415 822	LONG- TERM NON INT.BEARING DEBT	5 541 395	6 415 822
2 015 280	3 842 321	FINANCIAL LEASE LONG TERM	2 015 280	3 842 321
9 197 589	11 796 500	TOTAL LONG- TERM DEBT	9 197 589	11 796 500
237 285	4 286 938	ACCOUNTS PAYABLE	237 285	4 286 938
250 603	1 801 735	GOVERNMENT TAXES	250 603	1 801 735
2 650 548	1 323 105	OTHER CURRENT LIABILITIES	2 650 548	1 323 105
3 138 436	7 411 778	TOTAL CURRENT LIABILITIES	3 138 436	7 411 778
53 546 981	38 633 848	TOTAL EQUITY AND LIABILITIES	53 546 981	38 633 848

CASH FLOW, LIFECARE GROUP

NOK	1H 2023	1H 2022
	(Unaudited)	(Unaudited)
	2023	2022
CASH FLOW FROM OPERATING ACTIVITIES:		
EBIT	-14 263 077	-6 363 787
TAXES PAID	-	-
DEPRECIATION	997 907	607 471
CHANGE IN RECEIVABLES	2 135 184	-1 936 000
CHANGE IN ACCOUNTS PAYABLE	-1 390 352	2 314 513
CHANGES IN OTHER ACCRUED INCOME AND EXPENDITURE	-1 909 121	-704 594
CURRENCY CONVERSION DIFFERENCES		-
NET CASH FLOW FROM OPERATING ACTIVITIES	-14 429 459	-6 082 397
CASH FLOW FROM INVESTMENT ACTIVITIES:		
NEW NON-CURRENT ASSETS	-921 614	-5 148 551
INVESTMENTS IN FIXED FINANCIAL ASSETS	373 111	-5 004 491
NEW SHORT-TERM RECEIVABLES	-2 300 993	-3 955 297
<i>NET CASH FLOW FROM INVESTMENT ACTIVITIES</i>	<i>-2 849 496</i>	<i>-14 108 339</i>
CASH FLOW FROM FINANCING ACTIVITIES:		
NEW LONG-TERM DEBT	2 828 316	9 099 524
NEW SHORT TERM DEBT	-6 485 331	1 355 500
PAID- IN EQUITY		
DIVIDEND	-	
<i>NET CASH FLOW FROM FINANCING ACTIVITIES</i>	<i>-3 657 016</i>	<i>10 455 024</i>
NET CASH FLOW TOTAL	-20 935 971	-9 735 712
CASH AT BEGINNING OF THE PERIOD	47 630 404	21 041 862
CASH AT THE END OF THE PERIOD	26 694 433	11 306 150

NOTES TO THE CONDENSED INTERIM FINANCIAL STATEMENT

1. Organization and basis of preparation

Organization:

Lifecare AS (“Company”) is a Norwegian based clinical stage medical sensor company with subsidiaries in Bergen (Norway), Mainz, Reutlingen (Germany) and Bath (UK) (“Lifecare Group”). Lifecare’s main focus is to bring the next generation of Continuous Glucose Monitoring (“CGM”) systems to market. The Company’s sensor technology is suitable for identifying and monitoring the occurrence of a wide range of analytes and molecules in the human body.

Lifecare AS is listed on the Oslo Stock Exchange, Euronext Growth, with ticker LIFE.

Basis of presentation:

1st of January 2023 is the company's implementation date for conversion to International Financial Reporting Standards (IFRS) from NGAAP. More information on the opening balance as of January 1st, 2022, comparative balance as of 31 December 2022, and the effects of the transition to IFRS would be found in the first quarterly report of 2023.

These condensed interim financial statements prepared in accordance with International Accounting Standard 34 Interim Financial Reporting as issued by the International Accounting Standards Board (IASB) and as adopted by the European Union (EU). For a complete set of financial statements, these condensed interim financial statements should be read in conjunction with the annual statement of 2022 (NGAAP).

The condensed interim financial statements are unaudited. The audit will be carried out in connection with the 2023 yearend closing.

Fair Value:

The condensed interim financial statements reflect all adjustments which are, in the opinion of management, necessary for a fair presentation of the financial position, results of operations and cash flows for the dates and interim periods presented. Interim period results are not necessarily indicative of results of operations or cash flows for an annual period.

Use of estimates:

The preparation of financial statements in conformity with simplified IFRS requires management to make judgments, estimates and assumptions that affect the application of policies and reported amounts of assets, liabilities, income, and expenses. The estimates and associated assumptions are based on historical experience and various other factors that are believed to be reasonable under the circumstances, the results of which form the basis for making the judgments about carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates. The estimates and underlying assumptions are reviewed on an ongoing basis, considering current and expected future market conditions.

2. Intangible assets, plant, equipment and ROA

	Patents and licenses	Goodwill	Tangible assets	RIGHT OF USE ASSETS (IFRS 16)	Total
Cost 01.01.23	7 812 443	7 330 832	3 581 542	4 044 978	22 769 795
Purchased fixed assets					
Asset consolidation					
Cost 30.06.23	7 812 443	7 330 832	3 581 542	4 044 978	22 769 792
Acc. depreciation	2 053 919		668 302	499 853	3 222 074
Book value 30.06.23	5 758 524	7 330 832	2 913 240	3 545 125	19 547 721
Depreciation 2023	475 669		522 238	499 853	1 497 759

Lifecare Group has recognized two of its office facilities as a leasing contract according to IFRS 16. Lease liabilities according to IFRS 16 is measured as the present value of the remaining lease payments, discounted using the lessee's incremental borrowing rate.

Office rent due within 12 months are classified as short-term.

The company elected to use the recognition exemptions for lease contracts that, at the commencement date, have a lease term of 12 months or less and do not contain a purchase option ('short-term leases') and lease contracts for which the underlying asset is of low value ('low-value assets')

3. Equity

Equity Group	Share capital	Share premium reserve	Retained equity	Total equity
01.01.2023	47 146 297	40 306 997	-32 203 203	55 250 091
Effect of transition to IFRS			688 729	688 729
Share capital increase				
Currency conversion differences			-32 721	-32 721
Result 2023			-14 695 143	-14 695 143
Book value 30.06.2023	47 146 297	40 306 997	-37 580 534	41 210 956

4. Subsidiaries

Lifecare owns 100% of Lifecare NanoBioSensors GmbH. The company's result for 1H 2023 is 0,128 MNOK and the equity is 0,328 MNOK as of 30.06.23. The company has been consolidated into the consolidated accounts with effect from 01.07.2021.

Lifecare owns 100% of Lifecare Laboratory GmbH. The company's profit for 1H 2023 is NOK -0,284 MNOK and the equity is 4,8 MNOK as of 30.06.22. The company is consolidated into the consolidated accounts with effect from 01.02.2022.

Lifecare owns 100% in Lifecare Chemistry Ltd. The company was established 03.11.22 and will initiate operational activities from second part of 2023. The company is consolidated into the consolidated accounts with effect from 01.12.2022.

Lifecare owns 80% of the shares in Lifecare Veterinary AS. The company is consolidated into the consolidated accounts with effect from 01.06.2023.

5. Shareholders

The share capital of Lifecare as of 30.06.23 consists of 117,865,742 ordinary shares of NOK 0.40, in total NOK 47,146,297. The main shareholders per 30.06.23 was:

Shareholder	Shares	Stake
Teigland Eiendom AS	24 691 829	20,95 %
Lacal AS	18 187 712	15,43 %
Vpf Nordea Avkastning	8 974 413	7,61 %
Spit Air AS	3 087 735	2,62 %
Westhawk AS	3 018 480	2,56 %
Sandquist	2 916 400	2,47 %
Nordnet Livsforsikring AS	2 236 748	1,90 %
Deutsche Bank Aktiengesellschaft	2 120 718	1,80 %
Einarsen	2 000 000	1,70 %
BNP Paribas	1 812 600	1,54 %
Nexus Marketing	1 732 024	1,47 %
Andreassen	1 332 872	1,13 %
Cimter AS	1 331 355	1,13 %
Other (under 1% share)	44 423 856	38,69 %
Total shareholders	117 865 742	100,00 %

Primary insiders and related holdings	2023	2022	Stake 2023
Hanibal Invest AS (primary insider Hans Hekland)	200 000	200 000	0,17 %
Cimter AS (primary insider Joacim Holter)	1 331 355	1 331 355	1,13 %
Joacim Holter	317 997	317 997	0,27 %
Islay Venture GmbH (primary insider Andreas Pfützner)	2 620 499	2620499	2,22 %
Total shareholders	4 469 851	4 469 851	3,79 %

The CEO directly/indirectly owns 1.4% of the shares in the company.
The CSO indirectly owns 2,2 % of the shares in the company.

Clinical trials - Progress

Status

- The overall aim of the Clinical Development Study was to demonstrate device glucose assessment accuracy, while we optimized signal readings from needle sensors implants in the subcutaneous tissue (in humans).
- Clinical Development Study with the Sencell sensor (LFC-SEN-001) was finalized in 1H 2023. The study was designed to obtain a clear proof-of-concept in humans and to provide data for signal read-out and accuracy. Pre-requirements of design has been clarified, and automation of processes is in progress.
- Data from LFC-SEN-001 confirm a solid clinical accuracy of our technology (Sencell). The mean average of absolute error (MARD) between Sencell and matched relative reference values in the study was 9,6%, meaning that our sensor technology is in line with the gold standard for glucose monitoring (range 5%-10%).

Recent progress

- Sensors used in LFC-SEN-001 have been explanted from the test persons and transferred to in-vitro testing. The extended experiment confirms very encouraging sensor longevity, functionality of 24 weeks and was announced in July 2023.

Prospects

- We have filed the study application and expect regulatory approval for LFC-SEN-002 in Q3. The study objective of 002 is to explore sensor longevity and biocompatibility.
- We are now in progress towards ISO 13485 compliance and expect to obtain corresponding certification in Q4 2023.
- Manufacturing preparations are initiated. Lifecare plan to place orders for production software and equipment in Q3 and Q4 2023. Internal and external customization of production software and equipment will be ongoing throughout Q4 2023 and Q1 2024.
- Timelines are depending on regulatory approvals and, internal and external manufacturing capabilities.

Financial calendar

FINANCIAL YEAR 2023

08.11.2023 - Quarterly Report - Q3

Share capital increase history.

Historic overview capital increase

	2018	2022	2023
Total	33 MNOK	26,3 MNOK	45 MNOK
Share price	1,33 NOK	1,70 NOK	2,50 NOK

Shareholders as of 16.08.2023

	No.of shares	%
TEIGLAND EIENDOM AS	24 691 829	20,95 %
LACAL AS	18 187 712	15,43 %
VERDIPAPIRFONDET NORDEA AVKASTNING	8 973 413	7,61 %
SPIT AIR AS	3 087 735	2,62 %
WESTHAWK AS	3 018 480	2,56 %
SANDQUIST PATRICIA RODRIGUES DA COSTA	2 900 400	2,46 %
NORDNET LIVSFORSIKRING AS	2 165 702	1,84 %
DEUTSCHE BANK AKTIENGESELLSCHAFT	2 120 718	1,80 %
EINARSEN EVEN HARALD	2 010 000	1,71 %
BNP PARIBAS	1 812 600	1,54 %
NEXUS MARKETING	1 732 024	1,47 %
ANDREASSEN KURT NORMANN	1 332 872	1,13 %
CIMTER AS	1 331 355	1,13 %
CLEARSTREAM BANKING S.A.	1 085 056	0,92 %
LT FINANS AS	1 080 000	0,92 %
MAX INVEST AS	935 000	0,79 %
PROBE AS	905 012	0,77 %
HAN LEI	886 666	0,75 %
MOWINCKEL INVEST AS	883 626	0,75 %
HEJMA AS	800 000	0,68 %
Sum	79 940 200	68 %
Remaining shareholders (2000+)	37 925 542	32 %
Shareholders	117 865 742	100 %

Disclaimer

The information in this presentation has been prepared by Lifecare (the "Company"). This presentation does not constitute a recommendation regarding any securities of the Company. By accepting to attend this presentation and/or receive this information, you agree to be bound by the following limitations and provisions:

This presentation has been prepared based on information available as of the date hereof. No representation or warranty (expressor implied) is made as to, and no reliance should be placed on, any information, including projections, estimates, targets and opinions, contained herein, and no liability whatsoever is accepted as to any errors, omissions or misstatements contained herein, and, accordingly, none of the Company, or any advisor or any such persons' officers or employees accepts any liability whatsoever arising directly or indirectly from the use of this presentation. The Company is in its early stages of development and is considered to be a venture company. Venture companies in general entail a high degree of risk. It is highly recommended that potential investors seek further advice of risks associated with venture investments in general, and in particular specific risks for the Company. The information herein is subject to change, completion, supplements or amendments without notice. By relying on this presentation, you accept the risk that the presentation does not cover matters that could have been disclosed, have a more comprehensive investigation been carried out.

The presentation is based on the economic, regulatory, market and other conditions as in effect on the date hereof and may contain certain forward-looking statements. By their nature, forward-looking statements involve risk and uncertainty because they reflect the Company's current expectations and assumptions as to future events and circumstances that may not prove accurate. It should be understood that subsequent developments may affect the information contained in this document, which neither the Company nor its advisors are under an obligation to update, revise or affirm.

This complete presentation is for informational purposes only and does not constitute an offer to sell shares in of the company. This presentation is not a prospectus, disclosure document or offering document and does not purport to be complete.

This presentation has not been reviewed or approved by any regulatory authority or stock exchange. The (re)distribution of this presentation and/or any prospectus or other documentation into jurisdictions other than Norway may be restricted by law. This presentation does not constitute or form part of any offer or invitation to sell or issue, or any solicitation of any offer to acquire any securities offered by any person in any jurisdiction in which such an offer or solicitation is unlawful. Neither this presentation nor anything contained herein shall form the basis of any contract or commitment whatsoever. Persons into whose possession this presentation comes should inform themselves about and observe any such restrictions. Any failure to comply with these restrictions may constitute a violation of the securities laws of any such restrictions.

The presentation and any purported liability in connection with it is subject to Norwegian law and is subject to the exclusive jurisdiction of the Norwegian courts.

Contact

CONTACT

Name Joacim Holter

Title CEO

Mobil +47 40059040

e-mail joacim.holter@lifecare.no

Name Asle Steiestøl Wingsternes

Title Head of Comm. & Public affairs

Mobil +47 41 61 42 52

e-mail asle.wingsternes@lifecare.no

VISITING ADDRESS

Ytrebygdsvegen 215

5258 Blomsterdalen

LINKEDIN

<https://www.linkedin.com/company/lifecare-as/>

About Lifecare

Lifecare develops biosensor-technology for medical use. The biosensors are miniaturized to the size of a grain of rice due to the company's capacity to manipulate pressure-sensing elements in the nanoscale.

Our proprietary technologies have the potential to improve medical products by adding sensing functionalities to devices in all medical indications.

We have a particular focus on diabetes and are dedicated to helping the more than 500 million people living with diabetes.